Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Palbociclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention. Browse Palbociclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
229
Shown on this page
12
Current sort
Recently updated
Therapy scope
Palbociclib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Palbociclib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 193–204 of 229 matching trials for Palbociclib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional

A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

NCT01536743
View directory record Official record
Conditions
Ovarian Epithelial Carcinoma
Interventions
PD0332991
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 17, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

NCT02774681
View directory record Official record
Conditions
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Cognitive Assessment, Palbociclib, Quality-of-Life Assessment, Trastuzumab
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 17, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

PD0332991/Paclitaxel in Advanced Breast Cancer

NCT01320592
View directory record Official record
Conditions
Breast Cancer
Interventions
PD0332991, Paclitaxel
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 17, 2026, 4:37 AM EDT
Not listed Phase 1 Interventional

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

NCT01522989
View directory record Official record
Conditions
Advanced Solid Tumor Malignancies
Interventions
PD-0332991, 5-FU, Oxaliplatin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 17, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

NCT00721409
View directory record Official record
Conditions
Breast Cancer
Interventions
PD 0332991, letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
51
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 17, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

NCT01111188
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
PD 0332991, bortezomib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 17, 2026, 4:37 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

NCT02142868
View directory record Official record
Conditions
Advanced Breast Cancer (Female)
Interventions
Palbociclib, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Duluth, Georgia + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 17, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

NCT02334527
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma (UC)
Interventions
Palbociclib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Ann Arbor, Michigan • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 17, 2026, 4:37 AM EDT
Terminated Phase 1 Interventional

Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

NCT02030483
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Palbociclib, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 17, 2026, 4:37 AM EDT
Withdrawn Phase 2 Interventional

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

NCT03123744
View directory record Official record
Conditions
Cancer, Advanced
Interventions
Palbociclib 125mg
Drug
Lead sponsor
Razelle Kurzrock, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 17, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

NCT02065063
View directory record Official record
Conditions
Cancer
Interventions
Trametinib, Palbociclib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 17, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Palbociclib (PD-0332991) In Renal Impairment

NCT02085538
View directory record Official record
Conditions
Renal Impairment
Interventions
palbociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
DeLand, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 17, 2026, 4:37 AM EDT

About this Palbociclib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Palbociclib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Palbociclib.